abrdn Life Sciences Investors $HQL Shares Sold by Uhlmann Price Securities LLC

Uhlmann Price Securities LLC reduced its holdings in abrdn Life Sciences Investors (NYSE:HQL) by 13.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,711 shares of the company’s stock after selling 9,232 shares during the period. Uhlmann Price Securities LLC’s holdings in abrdn Life Sciences Investors were worth $790,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in HQL. Allspring Global Investments Holdings LLC lifted its position in abrdn Life Sciences Investors by 16.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 193,484 shares of the company’s stock valued at $2,455,000 after purchasing an additional 27,433 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new position in shares of abrdn Life Sciences Investors during the 1st quarter valued at about $134,000. Shaker Financial Services LLC acquired a new position in shares of abrdn Life Sciences Investors in the 1st quarter valued at about $297,000. LPL Financial LLC boosted its stake in shares of abrdn Life Sciences Investors by 14.4% in the first quarter. LPL Financial LLC now owns 328,402 shares of the company’s stock worth $4,167,000 after buying an additional 41,307 shares during the last quarter. Finally, Flagship Harbor Advisors LLC grew its holdings in abrdn Life Sciences Investors by 36.1% during the first quarter. Flagship Harbor Advisors LLC now owns 340,877 shares of the company’s stock worth $4,326,000 after acquiring an additional 90,436 shares during the period. Hedge funds and other institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Trading Down 0.3%

Shares of HQL stock opened at $16.53 on Monday. abrdn Life Sciences Investors has a twelve month low of $10.55 and a twelve month high of $16.92. The stock has a 50 day moving average of $14.59 and a 200 day moving average of $13.27.

abrdn Life Sciences Investors Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Friday, August 22nd were paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 10.2%. The ex-dividend date was Friday, August 22nd.

Insider Transactions at abrdn Life Sciences Investors

In related news, major shareholder Saba Capital Management, L.P. sold 41,623 shares of the firm’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $14.14, for a total transaction of $588,549.22. Following the sale, the insider owned 2,837,633 shares in the company, valued at approximately $40,124,130.62. This trade represents a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 179,906 shares of company stock worth $2,530,720 over the last quarter. Corporate insiders own 10.06% of the company’s stock.

About abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.